Why is RWE becoming a critical asset for market leaders? Clinical trials for rare diseases like GIST often have small sample sizes. This can make payers skeptical of the broad clinical benefit. Real-World Evidence (RWE)—data collected from actual clinical practice—fills this gap by showing how the drug performs in a more diverse, "real-world" patient population over longer periods....